{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:31Z","timestamp":1790697931949,"version":"4.1.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To describe a patient with idiopathic hypereosinophilic syndrome (HES) associated with panuveitis.\n                    <jats:bold>Methods<\/jats:bold>\n                    : An interventional case report is presented.\n                    <jats:bold>Results:<\/jats:bold>\n                    A 70-year-old woman presented with intermittent cutaneous eruptions, bilateral panuveitis, and a ground-glass pattern on chest CT-scan, with isolated eosinophilia of 12.8\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L. A complete uveitis workup was performed, and the patient was evaluated to rule out secondary causes of eosinophilia, with a thorough focus on infections, eosinophilic granulomatosis with polyangiitis, sarcoidosis, and drug-related syndromes. A bone marrow biopsy ruled out primary eosinophilia. Cytogenetics were also negative. Under steroid treatment there was no recurrence of skin rashes and panuveitis was satisfactorily resolved, but further use of mepolizumab was needed to normalize the hemogram.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The diagnosis of HES requires a comprehensive evaluation. Ocular involvement is rare. We present the ocular findings during the acute stage for the first time, along with the current management approach.\n                  <\/jats:p>","DOI":"10.1177\/24741264251366415","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:05:10Z","timestamp":1760616310000},"page":"881-886","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Panuveitis Associated With Idiopathic Hypereosinophilic Syndrome"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-5343","authenticated-orcid":false,"given":"Raquel","family":"Burggraaf-S\u00e1nchez de las Matas","sequence":"first","affiliation":[{"name":"Ocular Inflammation Unit, Ophthalmology Department, Hospital of Sagunto, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garijo-Bufort","sequence":"additional","affiliation":[{"name":"Ocular Inflammation Unit, Rheumatology Department, Hospital of Sagunto, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8634-9805","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Juan-Ribelles","sequence":"additional","affiliation":[{"name":"Ocular Inflammation Unit, Ophthalmology Department, Hospital of Sagunto, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Benavent-Corai","sequence":"additional","affiliation":[{"name":"Anatomical Pathology Department, Hospital of Sagunto, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Ortiz-Salvador","sequence":"additional","affiliation":[{"name":"Ocular Inflammation Unit, Ophthalmology Department, Hospital of Sagunto, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Gimeno-Brosel","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital of Sagunto, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27287"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15544"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1299176"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000100"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004042"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2020.2"},{"issue":"4","key":"e_1_3_2_8_2","first-page":"990","article-title":"Eosinophilic pneumonia with marked peripheral eosinophilia during the course of sarcoidosis","volume":"17","author":"Okauchi S","year":"2022","unstructured":"Okauchi S, Ohara G, Sasatani Y, Satoh H. Eosinophilic pneumonia with marked peripheral eosinophilia during the course of sarcoidosis. Maedica (Bucur). 2022;17(4):990-994.","journal-title":"Maedica (Bucur)"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000028"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4863.222050"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100673"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10050999"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000365324"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(82)34625-4"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102507"},{"key":"e_1_3_2_16_2","unstructured":"U.S. Food and Drug Administration. FDA approves first drug to treat group of rare blood disorders in nearly 14 years. PR Newswire. 2020. Accessed September 25. https:\/\/www.prnewswire.com\/news-releases\/fda-approves-first-drug-to-treat-group-of-rare-blood-disorders-in-nearly-14-years-301138449.html"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.037"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251366415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251366415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251366415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:51Z","timestamp":1790695551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251366415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/24741264251366415"],"URL":"https:\/\/doi.org\/10.1177\/24741264251366415","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}